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Background: Aggressive mature B-cell non-Hodgkin’s lymphomas (BCL) sharing features of Burkitt’s lymphoma (BL)
and diffuse large B-cell lymphoma (DLBCL) (intermediate BL/DLBCL) but deviating with respect to one or more
characteristics are increasingly recognized. The limited knowledge about these biologically heterogeneous lymphomas
hampers their assignment to a known entity, raising incertitude about optimal treatment approaches. We therefore
searched for discriminative, prognostic, and predictive factors for their better characterization.
Patients and methods: We analyzed 242 cytogenetically deﬁned aggressive mature BCL for differential protein
expression. Marker selection was based on recent gene-expression proﬁle studies. Predictive models for diagnosis
were established and validated by a different set of lymphomas.
Results: CSE1L- and inhibitor of DNA binding-3 (ID3)-overexpression was associated with the diagnosis of BL and
signal transduction and transcription-3 (STAT3) with DLBCL (P < 0.001 for all markers). All three markers were
associated with patient outcome in DLBCL. A new algorithm discriminating BL from DLBCL emerged, including the
expression of CSE1L, STAT3, and MYC translocation. This ‘new classiﬁer’ enabled the identiﬁcation of patients with
intermediate BL/DLBCL who beneﬁted from intensive chemotherapy regimens.
Conclusion: The proposed algorithm, which is based on markers with reliable staining properties for routine
diagnostics, represents a novel valid tool in separating BL from DLBCL. Most interestingly, it allows segregating
intermediate BL/DLBCL into groups with different treatment requirements.
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introduction
Accurate diagnosis of aggressive mature B-cell non-Hodgkin's
lymphomas (BCL) is mandatory for the choice of an optimal
treatment approach. In particular, the distinction of Burkitt’s
lymphoma (BL) from diffuse large B-cell lymphoma (DLBCL)
entails important prognostic and therapeutic implications.
Although both the entities are treated with curative intent,
different regimens are applied: most patients with DLBCL are
treated with rituximab plus cyclophosphamide,
hydroxydaunorubicin/doxorubicin, oncovin/vincristine and
prednisone (R-CHOP) chemotherapy, whereas a more
intensive chemotherapy (e.g. Hyper-cyclophosphamide,
vincristine, adriamycin/doxorubicin, dexamethasone) is
applied for the treatment of BL.
The deﬁnition of these two entities incorporates clinical
information, histomorphology, immunohistochemistry, as well
as genetic alterations including BCL2, BCL6, and MYC
translocations. With the advancement of molecular testing
widely applicable to formalin-ﬁxed, parafﬁn-embedded tissues,
lymphomas with overlapping morphological and genetic
features of both BL and DLBCL are increasingly recognized. In
the current World Health Organization (WHO) classiﬁcation,
they are classiﬁed as ‘B-cell lymphoma, unclassiﬁable, with
features intermediate between DLBCL and BL’ (intermediate
BL/DLBCL) [1]. The inherent complexity of this ill-deﬁned
group is reﬂected by their very heterogeneous nature,†These authors contributed equally to this work.
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comprising among others, double-hit lymphomas with MYC
aberration, with a particularly negative prognostic impact
[2, 3]. From the clinical point of view, a major issue regarding
this aggressive group of lymphomas is the lack of an optimal
treatment approach, and all attempts to deﬁne the borders of
intermediate BL/DLBCL with known diagnostic markers, such
as CD10, MUM1, Bcl2, Bcl6 protein expression or FISH for
BCL2, BCL6 and MYC, remained unsatisfactory so far [1, 3, 4].
Therefore, the purpose of this study is to ﬁnd additional
diagnostic and predictive markers in order to further
characterize aggressive mature BCL, with particular regard to
intermediate BL/DLBCL. Based on the reported gene-
expression proﬁling studies, which in the recent years were
found to be an accurate method to distinguish BL from
DLBCL, we analyzed the expression of three genes
[chromosome segregation 1-like (CSE1L), inhibitor of DNA
binding-3 (ID3), and signal transduction and transcription-3
(STAT3)] on a tissue micro array (TMA) [5, 6].
CSE1L is implicated in the nuclear-to-cytoplasmic trafﬁcking
of importin-alpha relevant for the nuclear transport of several
proliferation-associated proteins, oncogenes, and tumor
suppressor genes, such as p53. Although CSE1L was shown to
be overexpressed in various carcinomas [7] and melanomas
[8], few studies have reported high expression in high-grade
B-NHL when compared with low-grade B-NHL [9], primary
cutaneous B-cell lymphomas [10], or acute myeloid leukemias
[11]. ID3 belongs to the inhibitor of DNA binding (ID) family
of proteins which negatively regulate basic helix–loop–helix
transcription factors known as E-proteins and control many
aspects of lymphocyte proliferation, differentiation, and
survival [12]. ID family proteins have been shown to be
overexpressed in several solid tumors [13]; however, very little
is known about the role of ID3 in human lymphomas [14, 15].
Finally, STAT3 belongs to the signal transduction and
transcription (STAT) family of transcription factors and binds
to interleukin (IL)-6 and IL-10 responsive elements. In cell
culture assays, both cytokines and STAT3 were shown to be
expressed by non-germinal-center-B-cell (non-GCB)-derived
DLBCL cells. Moreover, a signature of STAT3 target genes
typiﬁes a subset of non-GCB DLBCL tumor cells with high
STAT3 protein levels [16].
We investigated a cohort of 242 aggressive mature BCL for
the expression of the mentioned markers CSE1L, ID3, and
STAT3 on a TMA. Their diagnosis was initially established by
morphology with the support of known immunophenotypical,
and genetic markers. In a univariate analysis, all the three
new markers were able to signiﬁcantly discriminate BL from
DLBCL, and their expression correlated with survival. Through
computational analysis, we developed a new algorithm for
aggressive mature BCL based on the combination of CSE1L
and STAT3 expression with MYC rearrangement by FISH,
which was superior in predicting the diagnosis of BL and
DLBCL than previous marker combinations. Finally, the use of
this algorithm appears to be of predictive value regarding the
therapeutic response. Based on these data, we propose the use
of these new markers as an additional diagnostic and predictive
tool, which, however, needs to be analyzed prospectively on a
larger number of cases before eventually being included in the
routine diagnostic procedures.
patients and methods
patients and biopsy specimen selection
A total of 288 patients with aggressive mature BCL diagnosed from 1990 to
2009 at the Institute of Surgical Pathology, University Hospital Zurich as
well as 10 BL cases derived from an afﬁliated hospital (Town Hospital
Triemli) in Zurich were included in the study. Twenty-three additional BL
or DLBCL cases collected during 2010 were used successively to validate
the diagnostic algorithm. All lymphomas were reviewed independently by
two pathologists (DS and MT) and diagnosed, according to the current
WHO 2008 classiﬁcation [1] as outlined in the supplementary data.
DLBCL were further subclassiﬁed into GCB and non-GCB types, according
to the Hans algorithm [17].
This study was in accordance with Swiss laws and approved by the ofﬁcial
authorities of the ethical committee of the Canton Zurich (StV2-2007).
treatment protocol
According to the ﬁrst-line chemotherapy used after the histological
diagnosis, four therapeutic groups were established (for details, see
supplementary data). The ‘ﬁrst’ group (89 patients) consisted of ‘CHOP-
like’ regimens, the ‘second’ group (16 patients) consisted of ‘intensive’
regimens, the ‘third’ group (6 patients) comprised vincristine, adriamycin/
doxorubicin, cyclophosphamide, etoposide, and prednisone (VACOP), and
the ‘fourth’ group (6 patients) comprised ‘low-intensity’ regimens
chlorambucil and prednisolone [18]. Each group was further subclassiﬁed
according to the use of rituximab.
immunohistochemistry
Based on gene-expression proﬁling [5, 6], we searched for reported genes
signiﬁcantly overexpressed in either BL or DLBCL and selected the
commercially available antibodies speciﬁc for CSE1L, ID3, and STAT3
which showed the best staining performance and reproducibility in normal
and neoplastic lymphatic tissues. For antibodies used and their evaluation
see supplementary Table S1, available at Annals of Oncology online.
Immunohistochemistry on 2.5-μm-thick TMA sections was carried out
using a Ventana ES instrument (Roche’s Ventana Medical Systems, Baar,
Switzerland) according to the standard protocols.
western blotting
Protein extracts from human BL-derived Raji cells were subjected to
Western blotting analysis. An anti-β-actin (mouse monoclonal, clone AC-
15, code A5441, Sigma-Aldrich, Hamburg, Germany) antibody was used as
a control for protein loading. (supplementary Figure S1, available at Annals
of Oncology online).
ﬂuorescence in situ hybridization (FISH)
FISH analysis was carried out as previously described [19, 20] and
evaluated by a cytogenetist (VM) who was blinded to the clinical
evaluation and remaining results. See supplementary Table S2, available at
Annals of Oncology online for probes used.
diagnostic algorithm for decision trees
and their validation
Computational analysis of the protein expression data lead to predictive
models for the diagnosis of interest. We chose binary decision trees, as
these easily handle missing values of the predictor variables and have
already been used in this context [17, 21]. Several binary decision trees for
the classiﬁcation of BL versus DLBCL were trained with different datasets
composed of protein expression and FISH results as predictor variables. The
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Table 1. Immunohistochemical and genetic characteristics of all cases
All cases
n (%)
BL
n (%)
DLBCL
n (%)
Intermediate DLBCL/BL
n (%)
P value
Total 242 (100.0) 22 (9.1) 193 (79.8) 27 (11.2)
Age at diagnosis <0.001
Median 60.5 37.5 63 54
Mean 58.1 38.6 61.2 51.3
<60 years 118 (45.9) 18 (81.8) 83 (43.0) 17 (63.0)
≥60 years 124 (54.1) 4 (18.2) 110 (57.0) 10 (37.0)
Gender 0.006
Female 107 (44.2) 3 (13.6) 90 (46.6) 14 (51.9)
Male 135 (55.8) 19 (86.4) 103 (53.4) 13 (48.1)
HIV 0.135
Positive 22 (9.1) 3 (13.6) 16 (8.3) 3 (11.1)
Negative 8 (3.3) 4 (18.2) 4 (2.1) 0 (0.0)
Not known 212 (87.6) 15 (68.2) 173 (89.6) 24 (88.9)
CD20 expression 1
Positive 242 (100.0) 22 (100.0) 193 (100.0) 27 (100.0)
Negative 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Bcl-1 expression 1
Positive 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Negative 242 (100.0) 22 (100.0) 193 (100.0) 27 (100.0)
CD5 expression 0.58
Positive 10 (4.1) 0 (0.0) 10 (5.2) 0 (0.0)
Negative 232 (95.9) 22 (100.0) 183 (94.8) 27 (100.0)
CD10 expression <0.001
Positive 99 (40.9) 22 (100) 57 (29.5) 20 (74.1)
Negative 143 (59.1) 0 (0.0) 136 (70.5) 7 (25.9)
MUM1 expression 0.403
Positive 58 (24.0) 4 (18.2) 50 (25.9) 4 (14.8)
Negative 184 (76.0) 18 (81.8) 143 (74.1) 23 (85.2)
Germinal-center B-cell (GCB) or non-GCB signature <0.001
GCB 122 (50.4) 22 (100) 78 (40.4) 22 (81.5)
non-GCB 120 (49.6) 0 (0.0) 115 (59.6) 5 (18.5)
Mib-1 score <0.001
<90% 203 (83.9) 0 (0.0) 189 (97.9) 14 (51.9)
At least 90% 39 (16.1) 22 (100) 4 (2.1) 13 (48.1)
MYC breakpoint <0.001
Translocation 48 (25.9) 22 (100) 8 (5.8) 18 (69.2)
No translocation 137 (74.1) 0 (0.0) 129 (94.2) 8 (30.8)
Bcl-2 expression 0.003
Positive 83 (34.3) 1* (4.5) 71 (36.8) 11 (40.7)
Negative 159 (65.7) 21 (95.5) 122 (63.2) 16 (59.3)
IGH–BCL2 fusion 0.078
Fusion 31 (14.5) 0 (0.0) 25 (14.5) 6 (24.0)
No fusion 183 (85.5) 17 (100.0) 147 (85.5) 19 (76.0)
Bcl-6 expression <0.001
Positive 100 (41.5) 15 (71.4) 67 (34.7) 18 (66.7)
Negative 141 (58.5) 6 (28.6) 126 (65.3) 9 (33.3)
BCL6 breakpoint 0.017
Translocation 41 (32.3) 0 (0.0) 33 (35.1) 8 (40.0)
No translocation 86 (67.7) 13 (100.0) 61 (64.9) 12 (60.0)
Number of translocations <0.001**
MYC alone 38 (36.9) 22 (100.0) 8 (12.9) 8 (42.1)
MYC and BCL2 3 (2.9) 0 (0.0) 0 (0.0) 3 (15.8)
MYC and BCL6 4 (3.9) 0 (0.0) 0 (0.0) 4 (21.1)
MYC, BCL2, and BCL6 3 (2.9) 0 (0.0) 0 (0.0) 3 (15.8)
BCL2 and BCL6 4 (3.9) 0 (0.0) 4 (6.5) 0 (0.0)
Continued
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Table 1. Continued
All cases
n (%)
BL
n (%)
DLBCL
n (%)
Intermediate DLBCL/BL
n (%)
P value
BCL6 alone 30 (29.1) 0 (0.0) 29 (46.8) 1 (5.3)
BCL2 alone 21 (20.4) 0 (0.0) 21 (33.9) 0 (0.0)
EBER (in situ) 0.02
Positive 17 (7.1) 5 (23.8) 11 (5.8) 1 (3.7)
Negative 222 (92.9) 16 (76.2) 180 (94.2) 26 (96.3)
Percentages were calculated on the basis of the number of evaluable cases (or on the basis of the total number of cases showing at least one translocation).
Percentages may not total 100 because of rounding.
P values were calculated using Fisher’s exact test (or the chi-square test, for **) and refer to differences between the BL, DLBCL and intermediate BL/DLBCL
cases.
The expression of CD20, CyclinD1, CD5, CD10, MUM1, Mib-1, Bcl-2, and Bcl-6 was determined by immunohistochemical analysis.
The MYC and BCL6 breakpoints and the IGH-BCL2 fusions were analyzed by interphase ﬂuorescence in situ hybridization (FISH).
*Weak intensity (Bcl2 expression).
BL, Burkitt’s lymphoma; DLBCL, diffuse large B-cell lymphoma.
Table 2. Clinical characteristics of the patients
All cases
n (%)
BL
n (%)
DLBCL
n (%)
Intermediate DLBCL/BL
n (%)
Total 220 18 178 24
Age at diagnosis
Median 63 41 66 56
Mean 59.6 41.9 62.3 53.3
<18 years 4 2 2 0
18 years to <60 years 93 12 66 15
≥60 years 123 4 110 9
Gender
Female 96 (43.6) 3 (16.6) 81 (45.5) 12 (50.0)
Male 124 (56.4) 15 (83.4) 97 (54.5) 12 (50.0)
Localization
Nodal only 107 (48.6) 10 (55.5) 84 (47.2) 13 (54.2)
Extranodal only 75 (34.1) 7 (38.9) 63 (35.4) 5 (20.8)
Nodal and extranodal 38 (17.3) 1 (5.6) 31 (17.4) 6 (25.0)
Therapy
CHOP-like regimen 89 (74.2) 5 (31.2) 75 (84.3) 9 (60.0)
Intensive regimen 16 (13.3) 9 (56.2) 2 (2.2) 5 (33.3)
VACOP 6 (5.0) 2 (12.5) 4 (4.5) 0 (0.0)
Low-intensity regimen 6 (5.0) 0 (0.0) 6 (6.7) 0 (0.0)
No treatment 3 (2.5) 0 (0.0) 2 (2.2) 1 (6.7)
Rituximab
No 62 (48.1) 9 (52.9) 44 (45.8) 9 (56.2)
Yes 67 (51.9) 8 (47.1) 52 (54.2) 7 (43.7)
Radiotherapy
No 94 (69.6) 13 (76.5) 70 (68.6) 11 (68.7)
Yes 41 (30.4) 4 (23.5) 32 (31.4) 5 (31.2)
Response to treatment
Complete remission 65 (29.6) 10 (55.6) 49 (27.5) 6 (25.0)
Recurrence 60 (27.2) 4 (22.2) 47 (26.4) 9 (37.5)
Death without disease-free interval 51 (23.2) 2 (11.1) 42 (23.6) 7 (29.1)
Loss of follow-up 44 (20.0) 2 (11.1) 40 (22.5) 2 (8.4)
Percentages were calculated on the basis of the number of cases with available information. The omission of cases without clinical information explains the
difference in ‘age at diagnosis’ and ‘gender’ existing between Tables 1 and 2. Percentages may not reach a total of 100 because of rounding.
BL, Burkitt’s lymphoma; DLBCL, diffuse large B-cell lymphoma.
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resulting decision trees were compared by their misclassiﬁcation error of 100-
fold bootstrapped cross-validation. The validation of the decision trees was
carried out using a separate group of 23 new lymphomas, for which the same
immunohistochemical and FISH analysis were carried out as in the initial
cohort. This validation cohort was evaluated as before by a cytogeneticist
(VM) and an assessor (CM) who were blinded to the diagnosis.
clinical data and survival analysis
The following patient characteristics were collected: age at diagnosis,
gender, lymphoma site, and therapeutic strategy. The response to treatment
and the occurrence of relapse or death was recorded. The Kaplan–Meier
method was used to estimate overall (OS) and progression-free survival
(PFS) (see supplementary data, available at Annals of Oncology online for
deﬁnition).
The log-rank test, stratiﬁed by the diagnostic group, was used to
compare the survival distributions. The differences between the strata were
tested with the chi-square test.
results
patients and diagnosis
Out of the 288 biopsies, 242 fulﬁlled the requirement for
further analysis with a minimum of 30% of tumor cells on the
tissue core. Of these, 22 were classiﬁed as BL, 193 as DLBCL,
and 27 as intermediate BL/DLBCL. Clinical data were available
for 220 patients (18 BL, 178 DLBCL, and 24 intermediate BL/
DLBCL). The mean follow-up was 5.2 years for BL patients,
4.3 years for DLBCL patients, and 3.3 years for intermediate
BL/DLBCL patients. A summary of the characteristics of
tumors and patients is presented in Tables 1 and 2.
expression of CSE1L, ID3, and STAT3 in normal
lymphatic tissues and in human BL-derived
raji cells
The speciﬁcity of these antibodies was conﬁrmed in a Western
blot analysis (supplementary Figure S1, available at Annals of
Oncology online).
In non-neoplastic tissue, CSE1L and ID3 were
predominantly expressed in GCB cells, whereas STAT3 was
expressed in cells of the inter-follicular area (Figure 1).
expression of CSE1L, ID3, and STAT3 in BL, DLBCL
and intermediate BL/DLBCL
A univariate analysis revealed a statistically signiﬁcant
differential expression of CSE1L, ID3, and STAT3 in BL
Figure 1. Results of immunohistochemical markers. ’CSE1L’ in reactive lymphoid tissue at (A) low (20×) and (B) high power (40×) magniﬁcation with
predominant, cytoplasmic reactivity in germinal-center dark cells and less strong in the light zone, but not in mantle zone cells or extra-follicular area.
Examples (40×) of both (C) Burkitt’s lymphoma (BL) and (D) diffuse large B-cell lymphoma (DLBCL). Inhibitor of DNA binding-3 (ID3) in reactive
lymphoid tissue at (E) low and (F) high power magniﬁcation with nuclear reactivity in both germinal-center and mantle zone cells. Lymphoma examples of
both (G) BL and (H) DLBCL. Signal transduction and transcription-3 (STAT3) in reactive lymphoid tissue at (I) low and (J) high power with only few cells
with cytoplasmic reactivity, mainly in the extra-follicular area. Examples of samples of both (K) BL and (L) DLBCL.
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versus DLBCL (Figure 1). CSE1L and ID3 were both found to
be more frequently expressed in BL than in DLBCL (for both P
< 0.001). STAT3, instead, was more frequently expressed in
DLBCL (P < 0.001), in particular more often in the non-GCB
than in the GCB subgroup (P < 0.001). For summary, see
supplementary Table S3, available at Annals of Oncology online.
survival analysis and correlation with marker
expression
For 220 patients, follow-up was available. Twenty-nine percent
of them relapsed and 23% of the patients had no disease-free
interval (supplementary Table S4, available at Annals of
Oncology online).
Overall, univariate survival analysis showed that ID3-positive
patients had signiﬁcantly longer OS and PFS than ID3-negative
patients (P = 0.020, with 5-year OS of 63.5% versus 44.7%;
P = 0.033, with 5-year PFS of 56.3% versus 36.8%), and CSE1L
expression was associated with longer PFS (P = 0.044, with
5-year PFS of 61.0% versus 40.1%). Finally, considering only
the group of DLBCL, the expression of STAT3 was associated
with longer OS (P = 0.052, with 5-year OS of 53.0% versus
38.4%) and PFS (P = 0.023; with 5-year PFS of 44.7% versus
30.7%). Neither OS (P = 0.920) nor PFS (P = 0.796) differed in
GCB versus non-GCB assessed by Hans classiﬁer.
diagnostic classiﬁers for BL and DLBCL
In order to evaluate whether the ‘combined’ expression of
CSE1L, ID3, and STAT3 enhances diagnostic precision, we
made use of binary decision trees to predict diagnosis. As this
computational approach is based on a binary system, the group
of insufﬁciently deﬁned intermediate BL/DLBCL was omitted,
and decision trees were trained to predict the diagnosis of either
BL or DLBCL. Different combination sets with the expression of
new markers, CSE1L, ID3, and STAT3, of conventional markers
(CD10, MUM1, Bcl-2, and Bcl-6), as well as FISH results for
BCL2, BCL6 and MYC translocations were introduced into the
algorithm, which in turn selected the markers to build the best
decision trees, also called classiﬁers (Figure 2).
From all different combinations of datasets applied, the
algorithm selected STAT3 and CSE1L expression, as well as
MYC translocation to build the decision tree with the highest
performance. This decision tree, which we called ‘new
classiﬁer’, showed the lowest misclassiﬁcation error of 8.7%
[standard deviation (SD) = 5.6% in 100-fold bootstrapped
cross-validation with a random level of 50.0% as balanced
error] (see Figure 3 for all different classiﬁers).
validation of the new classiﬁer
The validation of a predictive decision tree must be carried out
using a different set of cases than the ones used for their
training, and consists in the comparison of the original
diagnosis with the one predicted by the decision tree. For this
purpose, 23 additional aggressive mature BCL cases (5 BL and
18 DLBCL) recently diagnosed at the University Hospital
Zurich were employed. The ‘new classiﬁer’ predicted a correct
diagnosis in all BL and DLBCL cases, with a sensitivity and
speciﬁcity of 100% (see supplementary Table S5, available at
Annals of Oncology online).
impact of the new classiﬁer on diagnosis and
prognosis, in particular for the intermediate BL/
DLBCL group of lymphomas
We ﬁrst added the whole cohort with all three lymphoma types
including intermediate BL/DLBCLs to the training set, as the
Figure 2. Decision trees trained to predict the diagnosis of either Burkitt’s lymphoma (BL) or diffuse large B-cell lymphoma (DLBCL) with different sets
of markers and FISH results (n = 248). The ‘conventional classiﬁer without FISH data’ resulted when all conventional markers (CD10, MUM1, Bcl-2, and
Bcl-6) were submitted to the algorithm. When the FISH data (BCL2, BCL6, and MYC translocations) were in addition applied, the algorithm chose the
expression of CD10 and the data of FISH for MYC to build the ‘conventional classiﬁer with FISH data’. When the expression of new markers CSE1L,
inhibitor of DNA binding-3 (ID3), and signal transduction and transcription-3 (STAT3) as well as conventional markers were submitted to the binary
decision tree, only two new markers CSE1L and STAT3 were selected to build an algorithm, called ‘classiﬁer without FISH data’. Finally, the decision tree
with the highest performance resulted when all (conventional and new) markers in addition to FISH data were applied. This ‘new classiﬁer’ was composed
of the data of the expression of CSE1L and STAT3 and of the FISH data for MYC.
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latter were excluded from the initial set. Over the whole cohort,
six DLBCL cases were reclassiﬁed as predicted BL (pBL) and
two BL cases as predicted DLBCL (pDLBCL). By running the
‘new classiﬁer’ over the intermediate BL/DLBCL group only,
13/27 lymphomas were predicted as BL (pBL) and 14/27 as
DLBCL (pDLBCL). Interestingly, none of the pBL cases
showed MUM1 expression, in contrast to four positive (28.6%)
pDLBCL cases. GCB phenotype was present in 12/13 (92.3%)
pBL cases and 10/14 (71.4%) pDLBCL cases. All pBL carried a
MYC translocation (in contrast to 6/14 pDLBCL) and seven of
them presented with a simple karyotype (only 1/14 pDLBCL).
Both the groups presented ﬁve cases with triple or double hits
each. Finally, STAT3 expression was more frequent in the
pDLBCL (71.4%) than in the pBL (7.7%) group.
We next analyzed the inﬂuence of the new classiﬁer on
prognosis. We compared OS and PFS of predicted groups
receiving an intensive therapy versus CHOP-like therapy with
or without rituximab, as these two therapeutic groups
represented >90% of all therapeutic approaches in our cohort.
Regarding all lymphoma subtypes, the ‘new classiﬁer’ identiﬁed
patients with pBL showing a signiﬁcantly longer cumulative OS
and PFS when treated with intensive therapy than pBL treated
with CHOP-like therapy, with or without rituximab (P = 0.015
and P = 0.007, respectively) (Figure 4A). When the predicted
diagnoses were compared with the initial ones, the prognosis
for 4/6 pBL patients initially diagnosed as DLBCL was dismal
(no disease-free interval and disease-related death occurring
0.5, 1.2, 1.8, and 13.9 months after diagnosis). The therapeutic
approach was known in one case (R-CHOP, 1.2 months
survival). The remaining 2 pBL recurred after 22.56 and 77.5
months, respectively, and were treated with R-CHOP
chemotherapy. The two cases reclassiﬁed as pDLBCL,
originally diagnosed as BL, had an indolent course (recurrence
after 81 months, no recurrence after 192 months). Of note,
reclassiﬁed lymphomas presented with features otherwise
indistinguishable from the rest of the original diagnostic group.
Finally, the predictive value of the ‘new classiﬁer’ was also
evident when applied to the intermediate BL/DLBCL. In
particular, the ‘new classiﬁer’ was able to predict a signiﬁcantly
longer OS and PFS in pBL treated with intensive regimen
compared with pBL treated with CHOP-like regimens, with or
without rituximab (P = 0.040 for both OS and PFS, clinical
data available for 14 patients,) (Figure 4B).
discussion
In this report, we present three immunohistochemical markers
(CSE1, ID3, and STAT3) differentially expressed in BL and
DLBCL as well as a new decision tree, comprising the protein
expression of CSE1, STAT3, and MYC translocation, which
enables improved segregation of BL from DLBCL, and of
intermediate BL/DLBCL into two different prognostic groups.
CSE1L and ID3 were more frequently expressed in BL. In
contrast, STAT3 expression was associated with DLBCL,
especially the non-GCB subgroup. As expected, our ﬁndings
correlate with the increased transcription levels previously
reported in gene-expression studies [5, 6]. Moreover, we could
conﬁrm previous reports of STAT3 overexpression in non-
GCB-type DLBCL, both in a small series of primary
lymphomas and in cell lines [16, 22]. Increased CSE1L
expression has also been reported in highly proliferating
lymphomas, including DLBCL, and a gain of the gene locus
was reported in primary cutaneous B-cell lymphomas. In the
case of ID3, a very limited data are available about its
expression and potential role in lymphomas [9, 10, 14, 15].
Although the entity of BL is well characterized, its
distinction from DLBCL is not always unequivocal. In order to
improve the diagnostic accuracy of these entities, predictive
models were trained with different predictor sets (traditional
and new markers, FISH data) and cross-validated in 100-fold
bootstrapping, with the diagnosis of BL or DLBCL,
representing the prediction targets. The algorithm with highest
discriminative capacity comprised STAT3, CSE1L, and MYC
translocation. This algorithm, called ‘new classiﬁer’,
demonstrates the lowest misclassiﬁcation error for the
distinction of BL versus DLBCL when applied to the whole
cohort (Figures 2 and 3). The validation of the proposed
predictive model on 23 recently diagnosed aggressive mature
Figure 3. Performance of the decision trees. Performance of the
decision trees is based on the misclassiﬁcation error (0%–100%). The
misclassiﬁcation error is lowered by adding the new markers to the
conventional markers as indicated in Figure 2. This holds true for strategies
including FISH or not (A = conventional classiﬁer without FISH data, B =
classiﬁer without FISH data, C = conventional classiﬁer with FISH, and D
= new classiﬁer). Statistical signiﬁcance is given for two of the three
markers: P values from left to right for the differences between the two
adjacent markers: P = 2.8e−20 (difference A to B), P = 4.4e−10 (difference
B to C), P = 0.12 (difference C to D) (calculated with Welch’s two
sample t-test).
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BCL on the whole tissue sections displays a high agreement
with the results obtained on the TMA. Of note, the classiﬁer
appears superior in instances where FISH is unavailable
(Figure 3).
Most interestingly, the ‘new classiﬁer’ emerged as the only
algorithm with the predictive value for all lymphomas.
Notably, when the ‘new classiﬁer’ was applied to the whole
cohort including the intermediate BL/DLBCL group, it
predicted a more favorable outcome in patients identiﬁed as
pBL if treated with intensive therapy rather than the CHOP-
like regimen (Figure 4). The ‘new classiﬁer’ presented seems
therefore to be very promising in identifying patients who
might beneﬁt from high-dose chemotherapy regimens. This
stratiﬁcation into groups of patients responding to intensive
chemotherapy appears particularly meaningful for two reasons.
First, no standardized treatment recommendations exist for
patients diagnosed as intermediate BL/DBCL. In particular,
recent studies showed a certain beneﬁt for BL-oriented
therapies, but not for DLBCL-oriented R-CHOP regimens, in
patients with double-hit lymphomas with concurrent BCL2
and MYC translocations [23, 24]. However, as the group of
intermediate BL/DLBCLs includes also cases which might not
require an intensive therapy [24], the identiﬁcation of pDLBCL
cases will allow a more individualized therapeutic approach
even in patients with lymphomas with biological overlap.
Second, as shown by the few DLBCLs identiﬁed as pBLs, some
cases presenting with characteristic features of DLBCL carry a
very aggressive course and might require an intensive therapy.
Their identiﬁcation was not possible with conventional
methods, but with the proposed ‘new classiﬁer’. Hence, the
additional, predictive approach to lymphomas by the ‘new
classiﬁer’ might open new horizons in treatment planning and
allows affronting biologically overlapping lymphomas in an
alternative than the mere cell-of-origin-based way.
The validity of our study population is evidenced by the
signiﬁcantly better OS and PFS of patients with an initial
diagnosis of BL than those with DLBCL, whereas patients
diagnosed as intermediate BL/DLBCL showed the poorest
outcome as reported in the literature (data not shown) [23, 24].
Recent studies have suggested a potential role for CSE1L,
STAT3, and ID3 in oncology drug development. CSE1L
overexpression was shown to enhance apoptosis induced by
certain chemotherapeutic drugs [25, 26]. For ID3, a number
of studies in solid tumors suggest a role as a putative target
[27–29]. STAT3 has been proposed as a putative therapeutic
target, either indirectly by proteasome inhibitors (e.g.
bortezomib) and histone deacetylase inhibitors, or as a direct
molecular target of drugs currently under development [30, 31].
In summary, we present a new algorithm, which beyond its
diagnostic potency, bears predictive potential to treatment
response allowing tailored therapeutic approaches, in particular
for patients with intermediate BL/DLBCLs. Moreover, the
markers presented in this article represent easily detectable
molecules. Altogether, we believe that these data merit
conﬁrmation by prospective studies on larger cohorts.
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